28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among the 45 individuals with dementia, mixed dementia had the highest prevalence (42.4%), followed by AD-only (24.4%), non-AD other dementia (22.2%), and non-AD vascular dementia subtypes (11.1%). 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The ToAI framework followed a nine-step process: preparation, translation, native-speaker review, VIP team review, external panel review, pilot testing, proofreading, final formatting, and ongoing review and improvement. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results of gene set enrichment and gene set variation analyses indicated that immune-related pathways were upregulated in patients with VaD. 4 key findings →
Participants: 1,620 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this paper, we propose a deep super-resolution generative adversarial network (DSR-GAN) combined with a convolutional neural network (CNN) model designed to classify four stages of Alzheimer's disease (AD): Mild Dementia (MD), Moderate Dementia (MOD), Non-Demented (ND), and Very Mild Dementia (VMD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
weighted MRI can assess macro-structural brain atrophy, diffusion tensor imaging (DTI) unveils these hidden microstructural alterations. 2 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease and its clinical variants have characteristic spatial and temporal progression patterns of amyloid and tau driving symptomatology, but the distribution of microglia density, as measured by 18kDa translocator protein (TSPO) PET, is unknown. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimers disease (AD) represents the most prevalent form of dementia, affecting millions worldwide and posing significant public health challenges. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
At baseline, nearly one-third of caregivers reported moderate-to-severe burden (mean ZBI 31.4 ± 15.4), a prevalence that persisted at 6 months. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A preliminary search yielded 4772 studies, of which 12 (0.25%) met the criteria. 5 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregiving for persons living with dementia has long been conceived as a series of tasks that sustain the body. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Half of GUIDE-eligible PwD received care from multiple caregivers and high strain was common even among caregivers considered "low-complexity" under GUIDE. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
3 network types were identified: "Siloed"-small networks, limited task sharing (29.8% of networks); "Small but Mighty"-small networks, high task sharing (23.0% of networks); and "Complex"-large networks, diverse membership, members who share and specialize in task assistance (47.2%). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A significant association between increased caregiver burden and BPSD in patients with AD was demonstrated, which may be associated with decreased caregiver healthcare and social care-related QOL. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We synthesized caregivers' multiple challenges under five themes - (1) lack of information and awareness limit perceived need for services, (2) cultural norms and values influence decision to seek services, (3) complex processes and long waiting times hinder ability to reach services, (4) financial constraints and high costs force alternate care arrangements, and (5) inability to meet expectations and lack of family support limit engagement with services. 4 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The caregivers in intervention group showed significant reductions in distress scores for dressing, personal hygiene, communication, and behavioural and psychological care problems at both the 6th and 12th week assessments. 5 key findings →
Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Bisexual caregivers reported more stress, albeit better health than gay caregivers. 5 key findings →
Participants: 286 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With the increased use of technological supports in residential care homes, there is growing interest in the use of real-time location systems (RTLS) to enhance safety and streamline care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Formal caregivers exhibited significantly better psychological well-being and self-rated health compared to informal caregivers. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
People with dementia have complex medical, functional, and social needs and experience highly variable care quality and outcomes across the U.S. health care system. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 114 older adults (mean age 73 ± 10 years, 51% female) and their primary caregivers (mean age 49 ± 16 years, 70% female) participated, of whom 73 were recruited from health facilities and 41 from rural communities. 5 key findings →
Design: cross-sectional Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We demonstrate that senolytic treatment is an effective therapeutic strategy to mitigate cognitive impairment by reducing neuroinflammation and associated metabolic disturbances. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Medicare beneficiaries who received an AWV were 13% to 21% more likely than those without an AWV to be diagnosed at MCI stage versus ADRD stage. 5 key findings →
Design: case-control study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
NHB Hispanic, and NHW participants prevalences were APOE ε4 (32.2%, 27.4%, 17.6%), diabetes (26.1%, 35.0%, 13.9%), hypertension (79.0%, 63.6%, 58.2%), obesity (56.8%, 50.3%, 38.5%), and tobacco dependence (12.9%, 7.5%, 3.9%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Black caregivers reported shorter sleep duration but lower daily pain than White caregivers. 5 key findings →
Participants: 210 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →